Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase EARLY_PHASE1 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 2Skin Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Nivolumab 3Niacinamide 2HhAntag691 2urelumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1encorafenib 1cemiplimab 1binimetinib 1avelumab 1aldesleukin 1X-Rays 1Vitamin A 1Tranexamic Acid 1Sunscreening Agents 1Niacin 1Mohs Surgery 1Itraconazole 1Ipilimumab 1Interleukin-2 1Influenza Vaccines 1Indocyanine Green 1Immune Checkpoint Inhibitors 1Exercise 1Dimethyl Sulfoxide 1Cyclophosphamide 1Biopsy 1Ascorbic Acid 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Skin Neoplasms × binimetinib × Clear all
NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
14 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡